Eventos adversos tras la vacuna contra el virus del papiloma humano en adolescentes: revisión sistemática de la literatura
DOI:
https://doi.org/10.5216/ree.v26.76182Palabras clave:
Vacunación, Virus del Papiloma Humano, Adolescente, Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos, Reacción en el Punto de InyecciónResumen
Objetivo: El objetivo de este estudio fue investigar la ocurrencia de Eventos Supuestamente Atribuibles a la Vacunación o Inmunización asociados a la Vacuna contra el Virus del Papiloma Humano entre adolescentes de ambos sexos. Métodos: Se trata de una revisión sistemática realizada según la declaración Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Resultados: Se identificaron 11.016 artículos y, tras eliminar duplicados, quedaron 6.824. De ellos, 59 fueron seleccionados para lectura completa. La muestra estuvo compuesta por nueve estudios. Los resultados indican que la mayoría de los Eventos Supuestamente Atribuibles a la Vacunación o Inmunización fueron leves y moderados, prevaleciendo los eventos en el lugar de la inyección, como dolor y edema. Los Eventos Supuestamente Atribuibles a la Vacunación o Inmunización sistémicos más comunes fueron fiebre, dolor de cabeza, fatiga y mareos. Conclusión: La vacuna contra el Virus del Papiloma Humano para adolescentes es segura, lo que refuerza su importancia como estrategia para reducir las tasas de incidencia de cánceres asociados al Virus del Papiloma Humano.
Descargas
Citas
Howard N, Gallagher KE, Mounier-Jack S, Burchett HED, Kabakama S, LaMontagne DS, et al. What works for human papillomavirus vaccine introduction in low and middle-income countries? Papillomavirus Res. 2017 Dec 4;22-5. https://doi.org/10.1016/j.pvr.2017.06.003
Ferrer HB, Trotter C, Hickman M, Audrey S. Barriers and facilitators to HPV vaccination of young women in high-income countries: a qualitative systematic review and evidence synthesis. BMC Public Health 2014;14:700. https://doi.org/10.1186/1471-2458-14-700
Freeman LK. Adverse events following immunization. Can Fam Physician [Internet]. 2019 Mar [cited 2023 Jan 10];65(3):163. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6515964/
World Health Organization. How do vaccines work? Definition and Application of Terms for Vaccine Pharmacovigilance This report from the Council for International Organizations of Medical Sciences (CIOMS) in collaboration with WHO covers the activities and outputs of the CIOMS/WHO. [Internet]. 2020 Dec 8 [cited 2023 Jan 11]. Available from: https://www.who.int/news-room/feature-stories/detail/how-do-vaccines-work?adgroupsurvey={adgroupsurvey}&gclid=CjwKCAjwgGjBhBnEiwAMUvNW7XSFQhgfh94pbmGU2MxX9-NPCzGN06ocmn5DCuzKsWu1Riqp5iroxoCef4QAvD_BwE
World Health Organization. Global manual on surveillance of adverse events following immunization [Internet]. 2016 [cited 2023 Jan 14]. Available from:
https://iris.who.int/bitstream/handle/10665/206144/9789241507769_eng.pdf?sequence=1
Bisetto LH, Ciosak SI. Análise da ocorrência de evento adverso pós-vacinação decorrente de erro de imunização. Rev Bras Enferm. 2017 Jan-Feb;70(1):87-95. https://doi.org/10.1590/0034-7167-2016-0034
Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, Sundman J, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One [Internet]. 2012 Mar 28 [cited 2023 Feb 28];7(3):e33536. Available from: https://pubmed.ncbi.nlm.nih.gov/22470453/
Laz TH, Rahman M, Berenson AB. An update on human papillomavirus vaccine uptake among 11-17 year old girls in the United States: National Health Interview Survey, 2010. Vaccine. 2012 Apr 2;30(24):3534-40. https://doi.org/10.1016/j.vaccine.2012.03.067
Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: A pooled analysis. Lancet Glob Health. 2016 July;4(7):e453-63. https://doi.org/10.1016/S2214-109X(16)30099-7
Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019 Aug 16;68(32):698-702. https://doi.org/10.15585/mmwr.mm6832a3
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014 Sept 13;136(5):E359-86. https://doi.org/10.1002/ijc.29210
World Health Organization. Guide to introducing HPV vaccine into national immunization programmes [Internet]. 2016 [cited 2023 Abr 14]. Available from: https://apps.who.int/iris/handle/10665/253123
Lobão WM, Duarte FG, Burns JD, Santos CAST, Almeida MCC, Reingold A, et al. Low coverage of HPV vaccination in the national immunization programme in Brazil: Parental vaccine refusal or barriers in health-service based vaccine delivery? PLoS One [Internet]. 2018 Nov 12 [cited 2023 Jan 14];13(11):e0206726. Available from: https://pubmed.ncbi.nlm.nih.gov/30418980/
Sundaram N, Voo TC, Tam CC. Adolescent HPV vaccination: empowerment, equity and ethics. Hum Vaccin Immunother. 2020 Aug 2;16(8):1835-40. https://doi.org/10.1080/21645515.2019.1697596
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane [Internet]. 2022 [cited 2023 Apr 16]. Available from: https://training.cochrane.org/handbook
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71. https://doi.org/10.1136/bmj.n71
Ministério da Saúde, Secretaria de Ciência, Tecnologia e Insumos Estratégicos, Departamento de Ciência e Tecnologia. Diretrizes metodológicas - Elaboração de revisão sistemática e metanálise dos estudos observacionais comparativos sobre fatores de risco e prognóstico [Internet]. Brasília: Ministério da Saúde. 2014 [cited 2023 Dec 20]. Available from: https://bvsms.saude.gov.br/bvs/publicacoes/diretrizes_metodologicas_fatores_risco_prognostico.pdf
Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan — a web and mobile app for systematic reviews. Systematic Reviews. 2016;5:210. https://doi.org/10.1186/s13643-016-0384-4
Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-Analysis [Internet]. 2000 [cited 2023 Jan 10]. Available from: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
Neha R, Subeesh V, Beulah E, Gouri N, Maheswari E. Postlicensure surveillance of human papillomavirus vaccine using the Vaccine Adverse Event Reporting System, 2006-2017. Perspect Clin Res. 2020 Jan-Mar;11(1):24-30. https://doi.org/10.4103/picr.PICR_140_18
Naleway AL, Gold R, Drew L, Riedlinger K, Henninger ML, Gee J. Reported adverse events in young women following quadrivalent human papillomavirus vaccination. J Womens Health (Larchmt) [Internet]. 2012 Apr 13;21(4):425-32. https://doi.org/10.1089/jwh.2011.2895
Mauro AB, Fernandes EG, Miyaji KT, Arantes BA, Valente MG, Sato HK, et al. Adverse events following Quadrivalent HPV vaccination reported in Sao Paulo State, Brazil, in the first three years after introducing the vaccine for routine immunization (March 2014 to December 2016). Rev. Inst. Med. trop. S. Paulo. 2019 Sept 12;61. https://doi.org/10.1590/S1678-9946201961043
Martínez-Lavín M, Martínez-Martínez LA, Reyes-Loyola P. HPV vaccination syndrome. A questionnaire-based study. Clin Rheumatol. 2015 Sept 10;34(11):1981-3. https://doi.org/10.1007/s10067-015-3070-3
Jain KM, Paul P, LaMontagne DS. Monitoring adverse events following immunisation in developing countries: experience from human papillomavirus vaccination demonstration projects. Sex Health. 2013 Dec 14;(1):57-63. https://doi.org/10.1071/SH11161
Crawford NW, Hodgson K, Gold M, Buttery J, Wood N, AEFI-CAN network. Adverse events following HPV immunization in Australia: Establishment of a clinical network. Hum Vaccin Immunother. 2016 July 26;12(10):2662-5. https://doi.org/10.1080/21645515.2016.1192737
Jacobsen SU, Valentiner-Branth P, Mølbak K. Examining determinants for reporting suspected adverse events following HPV vaccination in Denmark. Vaccine. 2018 Sept 7;36(41):6158-62. https://doi.org/10.1016/j.vaccine.2018.08.061
Yoon D, Lee JH, Lee H, Shin JY. Association between human papillomavirus vaccination and serious adverse events in South Korean adolescent girls: nationwide cohort study. BMJ. 2021 Jan 29;372:m4931. https://doi.org/10.1136/bmj.m4931
Hineno A, Ikeda SI. A Long-Term Observation on the Possible Adverse Effects in Japanese Adolescent Girls after Human Papillomavirus Vaccination. Vaccines (Basel). 2021 Aug 4;9(8):856. https://doi.org/10.3390/vaccines9080856
Hibbs BF, Moro PL, Lewis P, Miller ER, Shimabukuro TT. Vaccination errors reported to the Vaccine Adverse Event Reporting System, (VAERS) United States, 2000-2013. Vaccine. 2015 May 14;33(28):3171-8. https://doi.org/10.1016/j.vaccine.2015.05.006
Leroy Z, Broder K, Menschik D, Shimabukuro T, Martin D. Febrile seizures after 2010-2011 influenza vaccine in young children, United States: a vaccine safety signal from the vaccine adverse event reporting system. Vaccine. 2012 Feb 20;30(11):2020-3. https://doi.org/10.1016/j.vaccine.2011.12.042
Moro PL, Broder K, Zheteyeva Y, Revzina N, Tepper N, Kissin D, et al. Adverse events following administration to pregnant women of influenza A (H1N1) 2009 monovalent vaccine reported to the Vaccine Adverse Event Reporting System. Am J Obstet Gynecol. 2011 June 21;205(5):473.e1-9. https://doi.org/10.1016/j.ajog.2011.06.047
Moura LD L, Codeço CT, Luz PM. Cobertura da vacina papilomavírus humano (HPV) no Brasil: heterogeneidade espacial e entre coortes etárias. Rev. bras. epidemiol. 2020 Dec 18;24:1-12. https://doi.org/10.1590/1980-549720210001
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2024 Revista Eletrônica de Enfermagem
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
